Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics

Marco Moschini, Martin Spahn, Agostino Mattei, John Cheville, Robert Jeffrey Karnes

Research output: Contribution to journalReview article

33 Citations (Scopus)

Abstract

Localized prostate cancer (PCa) is a clinically heterogeneous disease, which presents with variability in patient outcomes within the same risk stratification (low, intermediate or high) and even within the same Gleason scores. Genomic tools have been developed with the purpose of stratifying patients affected by this disease to help physicians personalize therapies and follow-up schemes. This review focuses on these tissue-based tools. At present, four genomic tools are commercially available: Decipher™, Oncotype DX®, Prolaris® and ProMark®. Decipher™ is a tool based on 22 genes and evaluates the risk of adverse outcomes (metastasis) after radical prostatectomy (RP). Oncotype DX® is based on 17 genes and focuses on the ability to predict outcomes (adverse pathology) in very low-low and low-intermediate PCa patients, while Prolaris® is built on a panel of 46 genes and is validated to evaluate outcomes for patients at low risk as well as patients who are affected by high risk PCa and post-RP. Finally, ProMark® is based on a multiplexed proteomics assay and predicts PCa aggressiveness in patients found with similar features to Oncotype DX®. These biomarkers can be helpful for post-biopsy decision-making in low risk patients and post-radical prostatectomy in selected risk groups. Further studies are needed to investigate the clinical benefit of these new technologies, the financial ramifications and how they should be utilized in clinics.

Original languageEnglish (US)
Article number67
JournalBMC Medicine
Volume14
Issue number1
DOIs
StatePublished - 2016

Fingerprint

Prostatic Neoplasms
Biomarkers
Prostatectomy
Genes
Aptitude
Neoplasm Grading
Proteomics
Decision Making
Pathology
Neoplasm Metastasis
Technology
Physicians
Biopsy

Keywords

  • Decipher
  • Genetic tools
  • Oncotype DX
  • Prolaris
  • Prostate cancer
  • Radical prostatectomy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics. / Moschini, Marco; Spahn, Martin; Mattei, Agostino; Cheville, John; Karnes, Robert Jeffrey.

In: BMC Medicine, Vol. 14, No. 1, 67, 2016.

Research output: Contribution to journalReview article

Moschini, Marco ; Spahn, Martin ; Mattei, Agostino ; Cheville, John ; Karnes, Robert Jeffrey. / Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics. In: BMC Medicine. 2016 ; Vol. 14, No. 1.
@article{1411c5ad0849404e8c71608782baa4fc,
title = "Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics",
abstract = "Localized prostate cancer (PCa) is a clinically heterogeneous disease, which presents with variability in patient outcomes within the same risk stratification (low, intermediate or high) and even within the same Gleason scores. Genomic tools have been developed with the purpose of stratifying patients affected by this disease to help physicians personalize therapies and follow-up schemes. This review focuses on these tissue-based tools. At present, four genomic tools are commercially available: Decipher™, Oncotype DX{\circledR}, Prolaris{\circledR} and ProMark{\circledR}. Decipher™ is a tool based on 22 genes and evaluates the risk of adverse outcomes (metastasis) after radical prostatectomy (RP). Oncotype DX{\circledR} is based on 17 genes and focuses on the ability to predict outcomes (adverse pathology) in very low-low and low-intermediate PCa patients, while Prolaris{\circledR} is built on a panel of 46 genes and is validated to evaluate outcomes for patients at low risk as well as patients who are affected by high risk PCa and post-RP. Finally, ProMark{\circledR} is based on a multiplexed proteomics assay and predicts PCa aggressiveness in patients found with similar features to Oncotype DX{\circledR}. These biomarkers can be helpful for post-biopsy decision-making in low risk patients and post-radical prostatectomy in selected risk groups. Further studies are needed to investigate the clinical benefit of these new technologies, the financial ramifications and how they should be utilized in clinics.",
keywords = "Decipher, Genetic tools, Oncotype DX, Prolaris, Prostate cancer, Radical prostatectomy",
author = "Marco Moschini and Martin Spahn and Agostino Mattei and John Cheville and Karnes, {Robert Jeffrey}",
year = "2016",
doi = "10.1186/s12916-016-0613-7",
language = "English (US)",
volume = "14",
journal = "BMC Medicine",
issn = "1741-7015",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics

AU - Moschini, Marco

AU - Spahn, Martin

AU - Mattei, Agostino

AU - Cheville, John

AU - Karnes, Robert Jeffrey

PY - 2016

Y1 - 2016

N2 - Localized prostate cancer (PCa) is a clinically heterogeneous disease, which presents with variability in patient outcomes within the same risk stratification (low, intermediate or high) and even within the same Gleason scores. Genomic tools have been developed with the purpose of stratifying patients affected by this disease to help physicians personalize therapies and follow-up schemes. This review focuses on these tissue-based tools. At present, four genomic tools are commercially available: Decipher™, Oncotype DX®, Prolaris® and ProMark®. Decipher™ is a tool based on 22 genes and evaluates the risk of adverse outcomes (metastasis) after radical prostatectomy (RP). Oncotype DX® is based on 17 genes and focuses on the ability to predict outcomes (adverse pathology) in very low-low and low-intermediate PCa patients, while Prolaris® is built on a panel of 46 genes and is validated to evaluate outcomes for patients at low risk as well as patients who are affected by high risk PCa and post-RP. Finally, ProMark® is based on a multiplexed proteomics assay and predicts PCa aggressiveness in patients found with similar features to Oncotype DX®. These biomarkers can be helpful for post-biopsy decision-making in low risk patients and post-radical prostatectomy in selected risk groups. Further studies are needed to investigate the clinical benefit of these new technologies, the financial ramifications and how they should be utilized in clinics.

AB - Localized prostate cancer (PCa) is a clinically heterogeneous disease, which presents with variability in patient outcomes within the same risk stratification (low, intermediate or high) and even within the same Gleason scores. Genomic tools have been developed with the purpose of stratifying patients affected by this disease to help physicians personalize therapies and follow-up schemes. This review focuses on these tissue-based tools. At present, four genomic tools are commercially available: Decipher™, Oncotype DX®, Prolaris® and ProMark®. Decipher™ is a tool based on 22 genes and evaluates the risk of adverse outcomes (metastasis) after radical prostatectomy (RP). Oncotype DX® is based on 17 genes and focuses on the ability to predict outcomes (adverse pathology) in very low-low and low-intermediate PCa patients, while Prolaris® is built on a panel of 46 genes and is validated to evaluate outcomes for patients at low risk as well as patients who are affected by high risk PCa and post-RP. Finally, ProMark® is based on a multiplexed proteomics assay and predicts PCa aggressiveness in patients found with similar features to Oncotype DX®. These biomarkers can be helpful for post-biopsy decision-making in low risk patients and post-radical prostatectomy in selected risk groups. Further studies are needed to investigate the clinical benefit of these new technologies, the financial ramifications and how they should be utilized in clinics.

KW - Decipher

KW - Genetic tools

KW - Oncotype DX

KW - Prolaris

KW - Prostate cancer

KW - Radical prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=85007489115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007489115&partnerID=8YFLogxK

U2 - 10.1186/s12916-016-0613-7

DO - 10.1186/s12916-016-0613-7

M3 - Review article

C2 - 27044421

AN - SCOPUS:85007489115

VL - 14

JO - BMC Medicine

JF - BMC Medicine

SN - 1741-7015

IS - 1

M1 - 67

ER -